Biosergen
Biosergen publishes interim report for first quarter 2023
REG
Summary of the Interim Report for Q2 2023
| 2023 | 2022 | 2023 | 2022 | 2022 | |
| TSEK | April-June | April-June | Jan-June | Jan-June | Jan-Dec |
| Profit/loss | |||||
| Other income | 2.456 | 1.409 | 7.771 | 2.726 | 5.183 |
| Profit/loss before depreciation (EBITDA | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Operating profit/loss befor net financials | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Net financials | 7 | 3 | 9 | 6 | 81 |
| Netprofit/loss for the period | -8.031 | -7.960 | -13.058 | -12.975 | -34.048 |
| Earnings per share (SEK) | -0,19 | -0,28 | -0,31 | -0,46 | -1,09 |
Highlights during Q2 2023
- March 29, Biosergen provides Phase 2 clinical development strategy update.
Highlights after the period
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
The Financial report can be found on our website: https://biosergen.net/investors/filings
| Datum | 2023-08-14, kl 08:14 |
| Källa | Cision |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.